Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q4 2020 · 10-K
Revenue—
Net Income-$22.71M-$22.71MN/M vs Q4 2019 EPS Diluted-$0.35-$0.35N/M vs Q4 2019 Operating Income-$22,776,000N/M Operating Cash Flowderived-$17,132,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Free Cash Flowderived-$18,132,000N/M ended Dec 31, 2020 · filed Mar 18, 2021 · 77 d after period end